drugset / Trial / NCT00816049
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy
Phase 3
Completed
775 enrolled
Rigshospitalet, Denmark
Nordic Society for Pediatric Hematology and Oncology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to increase the fraction of patients, who become MRD-negative during consolidation for the non-HR ALL group through individualized intensification of the 6MP-dosage days 30-85.
Timeline
- Start
- 2009-01
- Primary completion
- 2016-03-02
- Completion
- 2016-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | 25 mg/m2 | Oral |
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | 50 mg/m2 | Oral |
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | 75 mg/m2 | Oral |